DermaBio

Company Overview

Snapshot

Founded in July 2022 by Miriam Oron Ph.D. and Meital Portugal, DermaBio operates with 1–10 employees. The company has completed 2 funding rounds, attracting 1 investor. In November 2022, DermaBio secured Pre-Seed funding from MindUP.

Business overview

DermaBio is a Health Tech & Life Sciences company focused on precision medicine. Its AI-powered platform utilizes skin biomarker analysis, a proprietary clinical assay, and advanced data modeling to predict patient response to biologic therapies. This technology aims to improve treatment efficacy and reduce healthcare costs by providing actionable data to clinicians and payers. DermaBio serves the healthcare industry, operating within the Digital Healthcare and Medical Decision Support sectors, with a focus on non-invasive solutions for conditions like autoimmune diseases.

Company Intelligence Q&A

When was DermaBio founded?

DermaBio was founded in July 2022.

Who are the founders of DermaBio?

Miriam Oron Ph.D. and Meital Portugal are the co-founders of DermaBio.

What is DermaBio's primary focus?

DermaBio focuses on AI-based precision medicine, using skin biomarkers and predictive modeling to optimize biologic drug prescriptions.

What is DermaBio's employee count?

DermaBio currently has 1–10 employees.

What was DermaBio's most recent funding activity?

In April 2025, DermaBio completed a Pre-Seed funding round.